1. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia
- Author
-
Khan, Saira, Wolin, KY, Pakpahan, R, Grubb, RL, Colditz, GA, Ragard, L, Mabie, J, Breyer, BN, Andriole, GL, and Sutcliffe, S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Aging ,Prevention ,Urologic Diseases ,Prostate Cancer ,Obesity ,Nutrition ,Metabolic and endocrine ,Age Factors ,Body Size ,Humans ,Male ,Middle Aged ,Nocturia ,Prostatic Hyperplasia ,Benign Prostatic Hyperplasia ,Body size ,Prostate volume ,PLCO ,Urology & Nephrology ,Clinical sciences - Abstract
BackgroundExisting evidence suggests that there is an association between body size and prevalent Benign Prostatic Hyperplasia (BPH)-related outcomes and nocturia. However, there is limited evidence on the association between body size throughout the life-course and incident BPH-related outcomes.MethodsOur study population consisted of men without histories of prostate cancer, BPH-related outcomes, or nocturia in the intervention arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (n = 4710). Associations for body size in early- (age 20), mid- (age 50) and late-life (age ≥ 55, mean age 60.7 years) and weight change with incident BPH-related outcomes (including self-reported nocturia and physician diagnosis of BPH, digital rectal examination-estimated prostate volume ≥ 30 cc, and prostate-specific antigen [PSA] concentration > 1.4 ng/mL) were examined using Poisson regression with robust variance estimation.ResultsMen who were obese in late-life were 25% more likely to report nocturia (Relative Risk (RR): 1.25, 95% Confidence Interval (CI): 1.11-1.40; p-trendfor continuous BMI
- Published
- 2021